Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Active and passive immunization for atherosclerosis.

Kuang-Yuh Chyu¹, Jan Nilsson, Prediman K Shah

¹Cedars-Sinai Medical Center and David Geffen School of Medicine at UCLA, Division of Cardiology and Atherosclerosis Research Center, Suite 5347, 8700 Beverly Blvd., Los Angeles, CA 90048, USA.

Current Opinion in Molecular Therapeutics

|April 27, 2007

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Associations of the inflammasome-dependent cytokine IL-18 with risk of coronary heart disease.

Cardiovascular research·2026

Same author

LL-37 IgG levels are associated with clinical characteristics and T follicular cell response in acute coronary syndrome in adults.

Physiological reports·2026

Same author

Development and validation of two brief versions of the Nurse Professional Competence (NPC) Scale: The NPC-6 and NPC-12.

Nurse education today·2026

Same author

Adaptive immune response to the autoantigen LL-37 differentiates atherosclerotic cardiovascular disease phenotypes.

Clinical & translational immunology·2026

Same author

Deletion of PKM2 in Macrophages Promotes Stabilization but Not Regression of Atherosclerotic Plaques.

Circulation research·2026

Same author

Associations between the C-reactive protein-triglyceride glucose index and the incidence and progression trajectory of cardiometabolic multimorbidity: a multi-state model study.

Cardiovascular diabetology·2026

Same journal

Gene therapy: Have the risks associated with viral vectors been solved?

Current opinion in molecular therapeutics·2011

Same journal

Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.

Current opinion in molecular therapeutics·2010

Same journal

Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

Current opinion in molecular therapeutics·2010

Same journal

Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema.

Current opinion in molecular therapeutics·2010

Same journal

Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.

Current opinion in molecular therapeutics·2010

Same journal

Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.

Current opinion in molecular therapeutics·2010

See all related articles

Developing an atherosclerosis vaccine shows promise for treating cardiovascular disease. Immunization strategies offer a potential new therapy, though further research is needed on optimal antigens, adjuvants, and safety.

Area of Science:

Immunology
Cardiovascular Medicine
Vaccinology

Background:

Atherosclerosis involves complex immune mechanisms.
Current therapies for atherosclerotic disease are insufficient for a growing patient population.

Purpose of the Study:

To review experimental evidence on immune mechanisms in atherosclerosis.
To explore the potential of active or passive immunization strategies for atheroprotection.

Main Methods:

Review of experimental findings on immunomodulation in atherosclerosis.
Analysis of the feasibility and efficacy of immunization strategies.

Main Results:

Immunomodulation therapy demonstrates feasibility and effectiveness.

Related Experiment Videos

Active or passive immunization strategies show potential atheroprotective effects.

Conclusions:

A vaccine for atherosclerosis may be developed for clinical testing.
Immunization strategies offer a promising new therapeutic avenue for atherosclerotic vascular disease, pending answers to key questions regarding antigens, adjuvants, administration, durability, and safety.